Tech Company Financing Transactions
Ability Biologics Funding Round
On 6/18/2024, Ability Biologics announced $18 million in Seed investment from Amplitude Ventures, Alexandria Venture Investments and Charles River Laboratories.
Transaction Overview
Company Name
Announced On
6/18/2024
Transaction Type
Venture Equity
Amount
$18,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its R&D sector.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
3 Place Ville Marie 400
Montreal, QC, H3B 2E3
Canada
Montreal, QC, H3B 2E3
Canada
Phone
Undisclosed
Website
Email Address
Overview
Develop innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases. The premier biotherapeutic targeting company: Our powerful AbiLeap� discovery engine combines massively parallel, continuously learning artificial intelligence (AI) with an extensive database of antigen-antibody interactions to generate fully human, IgG-based multispecific antibodies of exquisite selectivity and affinity.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
David de Graaf
Chief Executive Officer
Giles Day
Chief Operating Officer
Patrick Tremblay
Chief Technical Officer
Jean-Philippe Bürckert
Vice President
Matthew Clark
VP - R & D
Patricia Giblin
Browse more venture capital transactions:
Prev: 6/18/2024: SurrealDB venture capital transaction
Next: 6/18/2024: Clip venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs